Bogenschutz MP

Department of Psychiatry, NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York, NY, USA.

18 papers · ORCID

ArticlePsychedelics

The science of psychedelic medicine.

Siegel JS, Liston C, Nicol GE +2

Europe PMC2026
ArticlePsilocybin

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Yaden DB, Graziosi M, Owen AM +39

Europe PMC2025
ArticlePsilocybin

Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder.

Gold ND, Pagni BA, Petridis PD +1

Europe PMC2025
ArticleAyahuasca

Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption.

Pagni BA, Halman A, Sarris J +3

Europe PMC2026
ArticlePsilocybin

Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.

Pagni BA, Zeifman RJ, Mennenga SE +6

Europe PMC2025
ArticlePsilocybin

Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer.

Petridis PD, Grinband J, Agin-Liebes G +5

Europe PMC2024
ArticlePsilocybin

A clinical research perspective on the regulation of medical and non-medical use of psychedelic drugs.

Bogenschutz MP

Europe PMC2025
ArticlePsilocybin

Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study.

Pagni BA, Petridis PD, Podrebarac SK +3

Europe PMC2024
ArticlePsilocybin

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.

O'Donnell KC, Anderson BT, Barrett FS +9

Europe PMC2024
ArticlePsilocybin

Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.

Gold ND, Podrebarac SK, White LA +6

Europe PMC2023
ArticlePsilocybin

Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.

Gold ND, Mallard AJ, Hermann JC +4

Europe PMC2023
ArticlePsychedelics

Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.

Kiluk BD, Kleykamp BA, Comer SD +24

Europe PMC2023
ArticlePsilocybin

Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.

O'Donnell KC, Mennenga SE, Owens LT +6

Europe PMC2022
ArticlePsilocybin

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.

Bogenschutz MP, Ross S, Bhatt S +10

Europe PMC2022
ArticleAyahuasca

Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca.

Barbosa PCR, Tófoli LF, Bogenschutz MP +5

Europe PMC2018
ArticlePsilocybin

The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions.

Nielson EM, May DG, Forcehimes AA +1

Europe PMC2018
ArticlePsilocybin

Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.

Bogenschutz MP, Podrebarac SK, Duane JH +5

Europe PMC2018
ArticlePsilocybin

Therapeutic Applications of Classic Hallucinogens.

Bogenschutz MP, Ross S

Europe PMC2018